Ganga Pharmaceuticals Ltd Financials
Company Logo

Ganga Pharmaceuticals Ltd Financial Statement

Ganga Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue1.60
Operating Expense1.42
Net Profit0.02
Net Profit Margin1.25
Earning Per Share0.05
EBIDTA0.17
Effective Tax Rate22.22
Invest in Ganga Pharmaceuticals Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Ganga Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual2.74
Operating Expenses Annual2.68
Operating Profit Annual0.30
Interest Annual0.18
Depreciation0.05
Net Profit Annual0.05
Tax Annual0.02

Ganga Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.03
Cash Flow from Operations-1.26
Cash Flow from Investing0.13
Cash Flow from Financing1.14
Cash Flow at the End0.03

Ganga Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)10.58
PBIT Margin (%)8.76
PBT Margin (%)-41.97
Net PROFIT Margin (%)1.82
Return On Networth / Equity (%)0.80
Return On Networth /Employed (%)3.18
Return On Assets (%)0.64
Total Debt / Equity (X)0.25
Asset Turnover Ratio (%)0.35

Ganga Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual0.61
Total Current Assets Annual5.75
Non Current Assets Annual2.90
Total Shareholders Funds Annual7.05
Total Assets Annual8.65

Ganga Pharmaceuticals Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 23, 2024, Ganga Pharmaceuticals Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.
Yes, Ganga Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.19.
In FY 2023 , Ganga Pharmaceuticals Ltd recorded a total revenue of approximately 2.74 Cr marking a significant milestone in the company's financial performance.
Ganga Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -100.0% and 0.0% annually, respectively..
Ganga Pharmaceuticals Ltd's current PE ratio is undefined.
Ganga Pharmaceuticals Ltd's ROCE averaged 3.3% from the FY ending March 2022 to 2024, with a median of 3.4%. It peaked at 3.5% in March 2023, reflecting strong capital efficiency over the period..
Ganga Pharmaceuticals Ltd's latest EBIT is Rs. 0.24 Cr, surpassing the average EBIT of Rs. 0.24 Cr over the 5 years..